Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study

J Chemother. 2020 May;32(3):160-162. doi: 10.1080/1120009X.2019.1709363. Epub 2019 Dec 30.

Authors

Marco Iannaccone¹, Matteo Boattini¹, Gabriele Bianco¹, Silvia Corcione², Rossana Cavallo¹, Cristina Costa¹

Affiliations

¹ Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.
² Department of Medical Sciences, Infectious Disease, University of Turin, Turin, Italy.

PMID: 31885333
DOI: 10.1080/1120009X.2019.1709363

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Age Factors
Aged
Aged, 80 and over
Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use*
Azabicyclo Compounds / pharmacology
Azabicyclo Compounds / therapeutic use*
Ceftazidime / pharmacology
Ceftazidime / therapeutic use*
Drug Combinations
Drug Resistance, Bacterial / physiology*
Female
Humans
Length of Stay
Male
Microbial Sensitivity Tests
Middle Aged
Sepsis / drug therapy*
Sepsis / microbiology
Sex Factors
beta-Lactamases / drug effects*

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Drug Combinations
avibactam, ceftazidime drug combination
Ceftazidime
beta-Lactamases